Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.
| Distributed by / for | PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 |
| NDC | 43063-844-14 |
| Full product label | ranitidine hydrochloride, USP ,150 mg tablets a) 14-count bottles ( NDC 43063-844-14); b) 30-count bottles (NDC 43063-844-30); c) 60 -count bottles( NDC 43063-844-60); d) 90-count bottles (NDC 43063-844-90); e) 100-count bottles ( NDC 43063-844-01), Rx Only, Distributed by: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 |
| Recalling firm | PD-Rx Pharmaceuticals, Inc. |
| Distribution | AZ, CA, FL, IL, IN, KY, ME, MS, OK, OR, PA, TN |
| Quantity | N/A |
| Recall initiated | 2020-01-10 |
| Report date | 2020-02-12 |
| Recall completed | 2021-03-23 |
| Recall number | D-0826-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Oklahoma City OK United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗